Vaccination Adverse Outcomes and Costs of Vaccine Injury Claims (VICs): Past, Present and Covid -19

¨Abstract

The US National Vaccine Injury Compensation Program (VICP) has paid out US$4,431,468,456 for 7,575 vaccine injuries from (financial years) 1989 through 2020... Based on past experience of vaccination injury, mass vaccination of billions of people for Covid-19 can be anticipated to produce vaccine injuries (including deaths). Based on the historical data of the VICP across 30 different vaccines, vaccinating a billion people with Covid-19 vaccines, can be anticipated to manifest a scenario of US$813 million of vaccine injuries (as an underestimate). Vaccinating the world's population (n=7.8 billion) with an initial Covid-19 vaccine dose may generate US$6.3 billion of vaccine injuries. A two dose Covid-19 vaccine (prime-boost regimen) may generate US$12.7 billion of vaccine injuries. These scenario extrapolations assume that the Covid-19 vaccines (although developed and administered under pandemic duress), are neither more nor less injurious than the vaccines (n=30) of VICP experience, which have been tested, certified, manufactured, stored and administered to US standards, and that there is no differential between the compensable value of US and non-US injuries...

3.1. Covid-19 Scenarios

A global Covid-19 vaccination programme would be the world’s biggest, boldest, and most ambitious vaccination programme ever embarked upon. Based on the past experience of vaccination injury, mass vaccination of billions of people for Covid-19 can be anticipated to produce vaccine injuries (including deaths). Mass vaccinations precipitate unintended adverse outcomes for some. A Hippocratic dictum of 'first, do no harm' cannot be realised in a mass vax rollout, and must be substituted with a cost/benefit analysis...

4. Conclusions

The indemnity shield of a vaccine injury scheme facilitates profits being privatised and costs being socialised. Care needs to be taken that societal benefits accruing from a Covid-19 vaccine are not at the cost of individualised harms.¨